摘要
本文观察4组(正常组、产褥组、功能组、肿瘤组)妇女口服羟苄丝肼前后血清泌乳激素(PRL)浓度的变化,以血清PRL峰/基比值为指标进行比较,发现肿瘤组妇女之峰/基比值显著低于其他3组。研究结果显示:羟苄丝肼刺激试验可用于功能性高催乳激素血症与垂体泌乳素微腺瘤的鉴别诊断。
The response of serum prolactin (PRL) to benserazide (150 mg orally) was tested in 34 hyperprolactinemic women, and compared to that in the normal and postpartum women. The results showed that the basal serum PRL and peak/basal serum PRL ratio in the patients (n=13) with pituitary tumor which were confirmed by CT scan were 472.05±236.7lng/ml and l.20±0.05 And they were 70.06± 10.38ng/ml and 6.49± 0.81 in functional group; 17.37±11.45ng/ml and 17.50±3.27 in normal group; 287.54±36.17ng/ml and 3.2910.67 in postpartum group, respectively. The mean peak/basal serum PRL ratio in tumoural group was highly significant lower than that in other group (P<0.01). It suggested that the benserazide can not stimulate the PRL release in patients with prolactinoma, but can do in functional hyperprolactinaemic patients. The benserazide stimulating test could be used to distinguish tumoural hyperprolactinaemia from functional hyperprolactinaemia, especially useful in diagnosis of microprolactinoma.
出处
《中山医科大学学报》
CSCD
1990年第2期67-70,共4页
Academic Journal of Sun Yat-sen University of Medical Sciences
基金
中山医科大学中青年科研基金
关键词
羟苄丝肼
泌乳素瘤
诊断
Benserazide Hyperprolactinaemia Prolactinomo
